Protego gets $130M for AL amyloidosis drug Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 1 December, 2025

presented by Writ­ing the Next Chap­ter in CLL Care: Bridg­ing Gaps Through In­no­va­tion and In­sights

news Gene writing startup Tessera strikes $150M partnership with Regeneron Generate to launch Phase 3 TSLP drug studies, as AI bio enters its clinical era Protego gets $130M for AL amyloidosis drug from leaders behind Vyndaqel

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine Dec 09 11:00am ET Strategic solutions for cost, time and quality challenges in drug development sponsored by Cambrex Dec 16 11:30am ET Maintaining EU GMP Annex I expectations while adopting new standards for prefilled syringe systems sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

The hematology sector heads into ASH under pressure, with data that could reshape R&D strategies and investment decisions across blood disorders. Join our expert analysis of the year’s most consequential readouts. Sign up today.

endpoints pharma Lundbeck backs out of bidding war for sleep disorder biotech Avadel Novo’s MFN prices to supersede IRA prices for Ozempic, Wegovy, CMS says •  Updated: CMS unveils negotiated prices for Ozempic, Wegovy and other drugs from second round of IRA talks Novo Nordisk, with new FDA voucher in hand, submits higher-dose Wegovy for approval Vaccine injury panel is slated for first meeting under RFK Jr. after nearly year-long delay

in case you missed it 1. China biotech seeks to rewire eye cells to create ‘one-size-fits-all’ rival to Luxturna 2. Cormorant eyes another $400M healthcare fund 3. Otsuka’s anti-APRIL antibody gets FDA approval for kidney disease IgAN 4. News Briefing Imfinzi's latest label expansion; FDA seeks more information on BiomX's nebulizer 5. FDA pushes back Ascendis' dwarfism drug decision date by three months 6.